AIM ImmunoTech Inc. (AIM) earnings
AIM earnings moved a median of -0.04% by the close. Quarterly and annual AIM reports and results, each read against the price at its own news timestamp. Back to the AIM overview →
21 measured AIM earnings events.
Where these AIM earnings landedvs 19 measured AIM earnings reactions
| Middle 50% of AIM earnings reactions | -6.55% to +2.34% |
|---|---|
| Median reaction (to close) | -0.04% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 AIM earnings events with a measured close landed between -6.55% and +2.34%; 47% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer | Press release | +1.78% | — | |
| Form 10-Q AIM ImmunoTech Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.78% | — | |
| Form 10-Q AIM ImmunoTech Inc. For: Mar 31 | SEC filing · Form 10-Q | +4.50% | +48.04% | |
| Form 10-K AIM ImmunoTech Inc. For: Dec 31 | SEC filing · Form 10-K | +2.12% | -22.81% | |
| AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program | Press release | -2.30% | -8.28% | |
| Form 10-Q AIM ImmunoTech Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.30% | -8.28% | |
| Form NT 10-Q AIM ImmunoTech Inc. For: Sep 30 | SEC filing · Form NT | -2.76% | -0.69% | |
| AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | -3.10% | +2.71% | |
| Form 10-Q AIM ImmunoTech Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.10% | +2.71% | |
| Form 10-K AIM ImmunoTech Inc. For: Dec 31 | SEC filing · Form 10-K | -2.67% | -4.98% | |
| AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 | Press release | -2.00% | +0.27% | |
| AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -4.08% | -7.08% | |
| Form 10-Q AIM ImmunoTech Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.08% | -7.08% | |
| AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast | Press release | +4.06% | +1.96% | |
| AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +2.73% | +0.97% | |
| Form 10-Q AIM ImmunoTech Inc. For: Jun 30 | SEC filing · Form 10-Q | +7.04% | +7.37% | |
| AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast | Press release | +0.59% | -0.04% | |
| AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | -2.41% | -6.02% | |
| Form 10-Q AIM ImmunoTech Inc. For: Mar 31 | SEC filing · Form 10-Q | -2.41% | -6.02% | |
| Form 10-K AIM ImmunoTech Inc. For: Dec 31 | SEC filing · Form 10-K | +1.75% | +0.02% | |
| Form 10-Q AIM ImmunoTech Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +4.17% |
Keep exploring
More AIM: analyst actions → · SEC filings → · AIM overview →